Pfizer's breast cancer drug has been deemed too expensive to market in Britain. Pfizer's breast cancer drug Ibrance, or palbociclib, is too expensive to justify its use on Britain's state-run health service, the country's healthcare cost-effectiveness watchdog said on Friday. The National Institute for Health and Care Excellence (NICE) said in draft guidance that although the medicine was likely to offer some improvement in overall survival, this could not be quantified from clinical trials. Ibrance's list price is 2950 pounds ($NZ5086.6) per 28 days. Pfizer UK's oncology head David Montgomery noted that the NICE decision was not final decision and said the US drugmaker was committed to working to try and find a solution to make the drug available.

Source: Otago Daily Times February 03, 2017 06:11 UTC